Page last updated: 2024-12-05

18-hydroxycorticosterone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

18-hydroxycorticosterone is a steroid hormone produced in the adrenal glands. It is a precursor to aldosterone, a mineralocorticoid responsible for regulating sodium and potassium levels in the body. 18-hydroxycorticosterone is synthesized from corticosterone through the action of the enzyme 18-hydroxylase. It has been shown to have both mineralocorticoid and glucocorticoid activity, although it is less potent than aldosterone or cortisol, respectively. Its importance lies in its role as a key intermediate in the biosynthesis of aldosterone. Research on 18-hydroxycorticosterone focuses on understanding its role in regulating blood pressure, electrolyte balance, and the stress response. Studies have also explored its potential therapeutic applications in conditions such as hypoaldosteronism and heart failure.'

Cross-References

ID SourceID
PubMed CID11222
CHEBI ID16485
SCHEMBL ID142427
MeSH IDM0023182

Synonyms (29)

Synonym
einecs 209-221-9
pregn-4-ene-3,20-dione, 11,18,21-trihydroxy-, (11beta)-
4u5t0o9si3 ,
unii-4u5t0o9si3
11beta,18,21-trihydroxypregn-4-ene-3,20-dione
CHEBI:16485
11beta,18,21-trihydroxy-pregn-4-ene-3,20-dione
LMST02030091
C01124
561-65-9
18-hydroxycorticosterone ,
11-hydroxy-17-(2-hydroxyacetyl)-13-(hydroxymethyl)-10-methyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one
(8s,9s,10r,11s,13r,14s,17s)-11-hydroxy-17-(2-hydroxyacetyl)-13-(hydroxymethyl)-10-methyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
pregn-4-ene-3,20-dione, 11,18,21-trihydroxy-, (11.beta.)-
pregn-4-ene-3,20-dione, 11.beta.,18,21-trihydroxy-
SCHEMBL142427
HFSXHZZDNDGLQN-ZVIOFETBSA-N
18-hydroxycorticosterone, 97% (cp)
AKOS027320497
11b,18,21-trihydroxy-pregn-4-ene-3,20-dione
CS-W013895
HY-W013179
DTXSID80897516
Q3597767
18-hydroxy corticosterone
(8s,9s,10r,11s,13r,14s,17s)-11-hydroxy-17-(2-hydroxyacetyl)-13-(hydroxymethyl)-10-methyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3(2h)-one
AS-6177
PD099481
4-pregnene-11beta,18,21-triol-3,20-dione

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The dose-response curve (peak plasma ACTH level vs."( Dose-response relationships between plasma adrenocorticotropin (ACTH), cortisol, aldosterone, and 18-hydroxycorticosterone after injection of ACTH-(1-39) or human corticotropin-releasing hormone in man.
Bähr, V; Boelke, T; Oelkers, W, 1988
)
0.49
" Synthetic beta-lipotropin (5 x 10(-10) mol/l) did not significantly change the dose-response curve for corticotropin (10(-13) mol/l-10(-9) mol/l) versus the three steroids measured."( Effects of beta-lipotropin, beta-endorphin, gamma 2-melanotropin and corticotropin on steroid production by isolated human adrenocortical cells.
Bähr, V; Eggens, U; Li, CH; Oelkers, W, 1987
)
0.27
" Suitable techniques for the investigation of secondary aldosteronism of unknown cause and for primary and secondary hypoaldosteronism are described, as well as the adjustment of dosage for replacement therapy where mineralocorticoid secretion is deficient."( Disorders of mineralocorticoid activity.
Drury, PL, 1985
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
18-hydroxy steroid
11beta-hydroxy steroidAny 11-hydroxy steroid in which the hydroxy group at position 11 has beta- configuration.
20-oxo steroidAn oxo steroid carrying an oxo group at position 20.
21-hydroxy steroid
3-oxo steroidAny oxo steroid where an oxo substituent is located at position 3.
primary alpha-hydroxy ketoneAn alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a -CH2 (methylene) group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (31)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Metabolism of steroids111135
Metabolism of steroid hormones2537
Mineralocorticoid biosynthesis616
Biological oxidations150276
Phase I - Functionalization of compounds69175
Cytochrome P450 - arranged by substrate type30110
Endogenous sterols1838
Steroidogenesis1142
Adrenal Hyperplasia Type 3 or Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency1142
Congenital Lipoid Adrenal Hyperplasia (CLAH) or Lipoid CAH1142
Adrenal Hyperplasia Type 5 or Congenital Adrenal Hyperplasia Due to 17 alpha-Hydroxylase Deficiency1142
17-alpha-Hydroxylase Deficiency (CYP17)1142
11-beta-Hydroxylase Deficiency (CYP11B1)1142
21-Hydroxylase Deficiency (CYP21)1142
Corticosterone Methyl Oxidase I Deficiency (CMO I)1142
Corticosterone Methyl Oxidase II Deficiency (CMO II)1142
Apparent Mineralocorticoid Excess Syndrome1142
3-beta-Hydroxysteroid Dehydrogenase Deficiency1142
Disease1278231
Diseases of metabolism69121
Metabolic disorders of biological oxidation enzymes647
Defective CYP11B2 causes CMO-1 deficiency06
Renin-angiotensin-aldosterone system (RAAS)011
Aldosterone from Steroidogenesis816
Mineralocorticoid biosynthesis08
Biosynthesis of aldosterone and cortisol010
Glucocorticoid & Mineralcorticoid Metabolism013
Glucocorticoid and Mineralcorticoid Metabolism04
Biochemical pathways: part I0466
Classical pathway of steroidogenesis with glucocorticoid and mineralocorticoid metabolism325

Research

Studies (313)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990227 (72.52)18.7374
1990's66 (21.09)18.2507
2000's12 (3.83)29.6817
2010's7 (2.24)24.3611
2020's1 (0.32)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.77 (24.57)
Research Supply Index5.80 (2.92)
Research Growth Index4.08 (4.65)
Search Engine Demand Index33.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (26.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (1.23%)5.53%
Reviews16 (4.94%)6.00%
Case Studies35 (10.80%)4.05%
Observational0 (0.00%)0.25%
Other269 (83.02%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]